Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07197697 | A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients | not yet recruiting | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07192848 | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | not yet recruiting | Phase 2 | 47 | Song PengOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | not yet recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT07189884 | Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy | not yet recruiting | Phase 1 / Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07190027 | Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | not yet recruiting | Phase 1 / Phase 2 | 246 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07187284 | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 62 | Zhongda HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07182708 | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC(HOFIBREN) | not yet recruiting | Phase 2 | 62 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT07179939 | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study | not yet recruiting | Phase 2 | 288 | Fudan UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07177950 | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases | not yet recruiting | Phase 1 / Phase 2 | 51 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07178717 | A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations(REFISH) | not yet recruiting | Phase 2 | 25 | Vall d'Hebron Institute of OncologyOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART E) | not yet recruiting | Phase 1 / Phase 2 | 42 | Princess Maxima Center for Pediatric OncologyOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07175636 | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07177092 | Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer(SURGAN-TKI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07177105 | Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC(SURGAN-ICI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07064876 | Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 25 | Xi JunjieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07161115 | Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) | not yet recruiting | Phase 2 | 60 | Longhao LiOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07172126 | Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets | not yet recruiting | Phase 1 / Phase 2 | 291 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07173556 | A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | not yet recruiting | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07164690 | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Sep 10, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07162571 | This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.(MSTH-CAR002) | not yet recruiting | Phase 1 / Phase 2 | 17 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07040644 | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07150403 | Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 74 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07158840 | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment(AGA TKI NSCLC) | not yet recruiting | Phase 2 | 60 | AkesoINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07160283 | The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer | not yet recruiting | Phase 2 | 96 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT07156604 | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156643 | A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. | not yet recruiting | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156682 | QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer | not yet recruiting | Phase 2 | 21 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157306 | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07153770 | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07156019 | Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.(NEUROBLASTOTEP) | not yet recruiting | Phase 2 | 30 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07151326 | Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy(CAPIO) | not yet recruiting | Phase 2 | 60 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07153289 | CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)(ResCPa) | not yet recruiting | Phase 1 / Phase 2 | 38 | University Hospital TuebingenOTHER | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07150377 | A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 41 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT07150416 | Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | not yet recruiting | Phase 2 | 38 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 29, 2025source: clinicaltrials